BR112016019390A2 - proteínas de fusão uti - Google Patents

proteínas de fusão uti

Info

Publication number
BR112016019390A2
BR112016019390A2 BR112016019390A BR112016019390A BR112016019390A2 BR 112016019390 A2 BR112016019390 A2 BR 112016019390A2 BR 112016019390 A BR112016019390 A BR 112016019390A BR 112016019390 A BR112016019390 A BR 112016019390A BR 112016019390 A2 BR112016019390 A2 BR 112016019390A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
uti
production
methods
pharmaceutical compositions
Prior art date
Application number
BR112016019390A
Other languages
English (en)
Other versions
BR112016019390B1 (pt
Inventor
Chamberlain Aaron
Schmidt Mathias
Liu Qiang
Original Assignee
Takeda Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh, Takeda Pharmaceuticals Co filed Critical Takeda Gmbh
Publication of BR112016019390A2 publication Critical patent/BR112016019390A2/pt
Publication of BR112016019390B1 publication Critical patent/BR112016019390B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • C07K14/8117Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/90Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a proteínas de fusão uti, sequências de dna para a produção das mesmas, e composições farmacêuticas e métodos de uso das mesmas.
BR112016019390-3A 2014-02-24 2015-02-23 Proteínas de fusão uti, composição farmacêutica compreendendo a referida proteína, ácido nucleico, vetor de expressão, célula hospedeira recombinante e método de produção de uma proteína de fusão uti BR112016019390B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461943617P 2014-02-24 2014-02-24
US61/943,617 2014-02-24
PCT/US2015/017152 WO2015127391A1 (en) 2014-02-24 2015-02-23 Uti fusion proteins

Publications (2)

Publication Number Publication Date
BR112016019390A2 true BR112016019390A2 (pt) 2017-10-24
BR112016019390B1 BR112016019390B1 (pt) 2023-11-14

Family

ID=52629709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019390-3A BR112016019390B1 (pt) 2014-02-24 2015-02-23 Proteínas de fusão uti, composição farmacêutica compreendendo a referida proteína, ácido nucleico, vetor de expressão, célula hospedeira recombinante e método de produção de uma proteína de fusão uti

Country Status (37)

Country Link
US (4) US9856310B2 (pt)
EP (2) EP3110434B1 (pt)
JP (4) JP6574431B2 (pt)
KR (2) KR20220151005A (pt)
CN (2) CN106232135B (pt)
AR (1) AR101597A1 (pt)
AU (4) AU2015218704B2 (pt)
BR (1) BR112016019390B1 (pt)
CA (2) CA2939639C (pt)
CL (1) CL2016002136A1 (pt)
CR (1) CR20160444A (pt)
CY (1) CY1120997T1 (pt)
DK (1) DK3110434T3 (pt)
DO (1) DOP2016000202A (pt)
EA (2) EA202091567A1 (pt)
EC (1) ECSP16076535A (pt)
ES (1) ES2700149T3 (pt)
GE (1) GEP20196970B (pt)
HR (1) HRP20182029T1 (pt)
IL (1) IL247321B (pt)
JO (1) JO3729B1 (pt)
LT (1) LT3110434T (pt)
MA (1) MA39347B2 (pt)
MX (2) MX2016010950A (pt)
MY (1) MY178774A (pt)
NZ (3) NZ760789A (pt)
PE (1) PE20170257A1 (pt)
PH (1) PH12016501629A1 (pt)
PL (1) PL3110434T3 (pt)
PT (1) PT3110434T (pt)
RS (1) RS58285B1 (pt)
SG (2) SG11201606691QA (pt)
SI (1) SI3110434T1 (pt)
TW (1) TWI694084B (pt)
UA (1) UA118866C2 (pt)
WO (1) WO2015127391A1 (pt)
ZA (1) ZA201606327B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178774A (en) * 2014-02-24 2020-10-20 Takeda Pharmaceuticals Co Uti fusion proteins
PE20200619A1 (es) * 2017-06-07 2020-03-11 Spark Therapeutics Inc AGENTES POTENCIADORES PARA LA TRANSFECCION CELULAR MEJORADA Y/O LA PRODUCCION DEL VECTOR rAAV
WO2020106881A1 (en) * 2018-11-20 2020-05-28 Diamedica Inc. Modified ulinastatin polypeptides
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
CA3174478A1 (en) * 2020-03-05 2021-09-10 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ES2066033T3 (es) * 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AU641568B2 (en) 1990-11-13 1993-09-23 Mochida Pharmaceutical Co., Ltd. Polypeptide,DNA fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
DE19725014A1 (de) 1997-06-13 1998-12-17 Bayer Ag Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten
PE20060287A1 (es) * 2004-03-30 2006-05-16 Glaxo Group Ltd INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM
WO2007011363A2 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
JP4067557B2 (ja) * 2005-06-03 2008-03-26 持田製薬株式会社 抗cd14抗体融合蛋白質
PT1981519T (pt) 2005-12-29 2018-02-23 Dyax Corp Inibição de protéases
BRPI0918947A2 (pt) * 2008-09-26 2015-12-01 Ucb Pharma Sa proteína de fusão de anticorpo
CN101721699B (zh) * 2008-10-13 2012-11-07 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用
CN102580085B (zh) * 2008-10-13 2013-09-18 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗脓毒症药物中的应用
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
KR102161657B1 (ko) * 2011-04-29 2020-10-06 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료적 뉴클레아제 조성물 및 방법
US8619331B2 (en) 2011-07-19 2013-12-31 Xerox Corporation Simulated paper texture using clear toner and glossmark on texture-less stock
CA2857168C (en) * 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
US9809641B2 (en) * 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华(上海)生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP2013253079A (ja) * 2012-05-14 2013-12-19 Xuhua (Shanghai) Biological Research & Development Center Co Ltd 生物学的に活性なヒト尿中トリプシンインヒビターのFc融合タンパク質並びにその調製および使用
MY178774A (en) * 2014-02-24 2020-10-20 Takeda Pharmaceuticals Co Uti fusion proteins

Also Published As

Publication number Publication date
MA39347A1 (fr) 2018-06-29
JO3729B1 (ar) 2021-01-31
PH12016501629A1 (en) 2017-02-06
MX2016010950A (es) 2017-04-25
MY178774A (en) 2020-10-20
HRP20182029T1 (hr) 2019-02-08
CA2939639A1 (en) 2015-08-27
ECSP16076535A (es) 2017-08-31
US9856310B2 (en) 2018-01-02
AU2015218704B2 (en) 2019-05-02
LT3110434T (lt) 2018-12-27
CN110092837B (zh) 2024-01-02
AU2015218704A1 (en) 2016-09-22
CL2016002136A1 (es) 2017-08-11
KR102461210B1 (ko) 2022-10-31
CY1120997T1 (el) 2019-12-11
US20220127334A1 (en) 2022-04-28
KR20160141718A (ko) 2016-12-09
US20180072795A1 (en) 2018-03-15
NZ724196A (en) 2022-01-28
EA201691702A1 (ru) 2017-01-30
AR101597A1 (es) 2016-12-28
WO2015127391A1 (en) 2015-08-27
US20200040062A1 (en) 2020-02-06
KR20220151005A (ko) 2022-11-11
SG11201606691QA (en) 2016-09-29
GEP20196970B (en) 2019-04-25
JP2022002513A (ja) 2022-01-11
AU2019204448B2 (en) 2021-06-10
DOP2016000202A (es) 2016-12-15
NZ760008A (en) 2023-03-31
NZ760789A (en) 2023-03-31
MA39347B2 (fr) 2020-05-29
CN110092837A (zh) 2019-08-06
UA118866C2 (uk) 2019-03-25
EP3110434A1 (en) 2017-01-04
AU2019204448A1 (en) 2019-07-11
CN106232135B (zh) 2019-12-10
SG10201708400QA (en) 2017-11-29
MX2019013124A (es) 2020-08-31
IL247321B (en) 2020-06-30
EA037256B1 (ru) 2021-02-26
PL3110434T3 (pl) 2019-01-31
ZA201606327B (en) 2019-01-30
JP2017512058A (ja) 2017-05-18
CR20160444A (es) 2017-04-21
IL247321A0 (en) 2016-09-29
PT3110434T (pt) 2018-12-19
US20160362475A1 (en) 2016-12-15
EP3443978A1 (en) 2019-02-20
EA202091567A1 (ru) 2021-07-30
ES2700149T3 (es) 2019-02-14
AU2021225156A1 (en) 2021-09-30
JP2019187427A (ja) 2019-10-31
EP3110434B1 (en) 2018-09-19
DK3110434T3 (en) 2019-01-14
SI3110434T1 (sl) 2019-02-28
BR112016019390B1 (pt) 2023-11-14
US10351618B2 (en) 2019-07-16
AU2021225156B2 (en) 2022-11-24
TW201630931A (zh) 2016-09-01
CA3178241A1 (en) 2015-08-27
CA2939639C (en) 2023-01-24
RS58285B1 (sr) 2019-03-29
CN106232135A (zh) 2016-12-14
AU2023200875A1 (en) 2023-04-27
JP2023123763A (ja) 2023-09-05
PE20170257A1 (es) 2017-03-30
JP6574431B2 (ja) 2019-09-11
TWI694084B (zh) 2020-05-21
JP6938565B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
DK3292137T3 (da) Proteiner specifikke for cd137
DK3341482T3 (da) Kunstige nukleinsyremolekyler
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
EP3194980A4 (en) Improved single molecule peptide sequencing
DK3207053T3 (da) Hidtil ukendte immunogene peptider
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
MX2016016886A (es) Anticuerpos anti-axl.
DK3188836T3 (da) Dna-syntese
DK3182985T3 (da) Fibroinafledt proteinsammensætning
DK3237432T3 (da) Proteinfremstilling
DK3142785T3 (da) Fremgangsmåde til fremstilling af alkenoler og anvendelse deraf til fremstilling af 1,3-butadien
DK3107562T3 (da) P97-ids-fusionsproteiner
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
BR112016019390A2 (pt) proteínas de fusão uti
DK3186241T3 (da) Prober til billeddannelse af huntington-protein
DK3164410T3 (da) Protein-indvinding
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
EP3178923A4 (en) Use of susd2 protein as marker
EP3125923A4 (en) Lyophilized pharmaceutical composition of fc-peptide fusion protein
DK3149163T3 (da) Prohæmostatiske proteiner til behandling af blødning
UY36277A (es) Proteínas de fusión uti
EP3259355A4 (en) Methods related to dna sequencing
TH1501001508A (th) วิธีการสำหรับการผลิตกรด l-อะมิโน
TH1501007959A (th) สีแอซิด, กรรมวิธีสำหรับผลิตพวกมันและการใช้ของพวกมัน

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023015739-7 PROTOCOLO 870230068833 EM 04/08/2023 14:41.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2015, OBSERVADAS AS CONDICOES LEGAIS